NCT00385489

Brief Summary

The purpose of this study is to evaluate the safety of LXR-623 in healthy Japanese subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Aug 2006

Shorter than P25 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2006

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2006

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 5, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 9, 2006

Completed
Last Updated

August 7, 2009

Status Verified

August 1, 2009

Enrollment Period

1 month

First QC Date

October 5, 2006

Last Update Submit

August 6, 2009

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

  • Safety

Interventions

LXR-623DRUG

Eligibility Criteria

Age20 Years - 45 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy, Japanese Males aged 20-45 years

You may not qualify if:

  • A history or active presence of clinically important medical disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Toshima-ku, Tokyo, 171-0014, Japan

Location

MeSH Terms

Interventions

2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 5, 2006

First Posted

October 9, 2006

Study Start

August 1, 2006

Primary Completion

September 1, 2006

Study Completion

September 1, 2006

Last Updated

August 7, 2009

Record last verified: 2009-08

Locations

JP(1)